IgG anti-50 kd lymphocyte membrane peptide antibody in patients with Sézary syndrome.
BACKGROUND
Recent evidence suggests that as cutaneous T-cell lymphoma progresses, cell-mediated immunity is reduced and humoral responses are augmented.


OBJECTIVE
The present study was designed to compare the IgG response in Sézary syndrome with that in mycosis fungoides.


METHODS
The IgG antilymphocyte response was studied in six patients with Sézary syndrome and in 11 patients with mycosis fungoides by means of immunoblot analysis, enzyme-linked immunosorbent assay, immunohistochemistry, and flow cytometry.


RESULTS
An IgG antilymphocyte response to a 50 kd peptide was seen in five of the six patients with Sézary syndrome; however, none of the 11 patients with mycosis fungoides expressed this response.


CONCLUSIONS
An enhanced IgG immune response to 50 kd lymphocyte peptide may be helpful in identifying disease progression in patients with cutaneous T-cell lymphoma.
D'Ambra-Cabry
K
K
University of Pittsburgh Department of Dermatology, PA, USA.
Tharp
M D
MD
Jagasothy
B V
BV
Deng
J S
JS
D000328:Adult; D000912:Antibodies, Neoplasm / Q000276:immunology*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007111:Immunity, Cellular; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000276:immunology*; D008565:Membrane Proteins / Q000276:immunology; D009182:Mycosis Fungoides / Q000276:immunology / Q000473:pathology; D012751:Sezary Syndrome / Q000276:immunology* / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology
D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D008565:Membrane Proteins